F. Hoffmann-La Roche Ltd., Pharma Research, Grenzacherstr. 124, CH-4070 Basel, Switzerland.
Bioorg Med Chem Lett. 2013 Jul 15;23(14):4239-43. doi: 10.1016/j.bmcl.2013.05.003. Epub 2013 May 18.
A series of amides bearing a variety of amidine head groups was investigated as BACE1 inhibitors with respect to inhibitory activity in a BACE1 enzyme as well as a cell-based assay. Determination of their basicity as well as their properties as substrates of P-glycoprotein revealed that a 2-amino-1,3-oxazine head group would be a suitable starting point for further development of brain penetrating compounds for potential Alzheimer's disease treatment.
研究了一系列带有各种脒基头部基团的酰胺作为 BACE1 抑制剂,以评估它们在 BACE1 酶和基于细胞的测定中的抑制活性。测定它们的碱性以及作为 P-糖蛋白底物的性质表明,2-氨基-1,3-恶嗪头部基团将是进一步开发用于潜在阿尔茨海默病治疗的穿透脑化合物的合适起点。